Hekster Y A, Vree T B
Drug Intell Clin Pharm. 1986 Sep;20(9):679-82. doi: 10.1177/106002808602000909.
This report describes the use of drug utilization studies in clinical practice, with special emphasis on future developments. It has been shown that pharmacy services affect prescribing patterns, have great potential for reducing health care costs, and are in a position to produce financial savings in drug therapy and drug use. However, it is essential to balance the drug utilization figures against the resulting outcome, and attention should be focused on the assessment of therapeutic results. To make therapeutic result assessment possible, end points need to be defined. Several examples of such end points are given and include incidence of nosocomial infections and postoperative wound infections. New parameters have been established to assess the severity of the illness and to follow the effect of drugs on the disease process in the form of an Index of Disease Activity (IDA). IDAs have been prepared for Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis. It then becomes possible to link drug utilization data with a drug's influence on a disease, making drug utilization research a recognized discipline within the medical field.
本报告描述了药物利用研究在临床实践中的应用，特别强调了未来的发展。研究表明，药学服务会影响处方模式，在降低医疗成本方面具有巨大潜力，并且能够在药物治疗和药物使用方面节省资金。然而，必须将药物利用数据与产生的结果进行平衡，并且应将注意力集中在治疗结果的评估上。为了能够进行治疗结果评估，需要定义终点。给出了一些此类终点的例子，包括医院感染和术后伤口感染的发生率。已经建立了新的参数来评估疾病的严重程度，并以疾病活动指数（IDA）的形式跟踪药物对疾病进程的影响。已经为克罗恩病、类风湿性关节炎和强直性脊柱炎制定了IDA。这样就有可能将药物利用数据与药物对疾病的影响联系起来，使药物利用研究成为医学领域中一门公认的学科。
